Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 27901-27910 Newer>

The Motley Fool January 2, 2008 Rich Duprey	Five-Star Gaming Stocks: GigaMedia Online gaming operator GigaMedia is flourishing, despite being outlawed in the U.S. Investors, you may be banned from playing the games, but not from owning the stock.
The Motley Fool January 2, 2008 Rimmy Malhotra	Standing Out by Standing Apart The key to value investing is finding something that is selling cheap because not everyone has jumped on the bandwagon yet. But that alone isn't enough. Read on for more.
The Motley Fool January 2, 2008 Sham Gad	Buffett Bets on the U.S. In typical fashion, Warren Buffett made some big acquisitions last week, and he made them quickly. Read on to see what Warren bought.
The Motley Fool January 2, 2008 Rick Aristotle Munarriz	Google Goes Old School in the Old World Google is in talks with several European publishers to buy ad space in their print publications; Google will then turn around and auction off that space to its online advertisers.
The Motley Fool January 2, 2008 Morgan Housel	Buffett's Baseball Lesson While it isn't breaking news that Warren Buffett is a financial wizard, many investors don't fully appreciate the magnitude of his success, or his incredible consistency over the years.
The Motley Fool January 2, 2008 Morgan Housel	Bank Stock Rebound in 2008? 2007 marked one of the worst years for financial stocks in recent memory.
The Motley Fool January 2, 2008 Morgan Housel	When Is a Sale Not a Sale? A sluggish holiday season has retailers slashing prices; great for consumers, but not for investors.
The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
CFO January 1, 2008 Alix Stuart	Refusing to Roll Over One CFO refuses to settle with the Securities and Exchange Commission over accusations of backdating.
The Motley Fool December 31, 2007 Brian Lawler	Cephalon's Date With the FDA In the last day of the year, Cephalon announces that it has submitted another New Drug Application for oncology treatment Treanda. Expect to hear back from FDA on this priority review before the middle of 2008.
<Older 27901-27910 Newer> Return to current articles.